Tumor Antigen by Immunoassay CA 19-9
CPT: 86301

CMS National Coverage Policy

Coverage Indications, Limitations, and/or Medical Necessity
Immonoassay determinations of the serum levels of certain proteins or carbohydrates serve as tumor markers. When elevated, serum concentration of these markers may reflect tumor size and grade. This policy specifically addresses the following tumor antigen: CA19-9.

Indications
Multiple tumor markers are available for monitoring the response of certain malignancies to therapy and assessing whether residual tumor exists post-surgical therapy.

Levels are useful in following the course of patients with established diagnosis of pancreatic and biliary ductal carcinoma. The test is not indicated for diagnosing these two diseases.

Limitations
These services are not covered for the evaluation of patients with signs or symptoms suggestive of malignancy. The service may be ordered at times necessary to assess either the presence of recurrent disease or the patient’s response to treatment with subsequent treatment cycles.
The ICD10 codes listed below are the top diagnosis codes currently utilized by ordering physicians for the limited coverage test highlighted above that are also listed as medically supportive under Medicare’s limited coverage policy. **If you are ordering this test for diagnostic reasons that are not covered under Medicare policy, an Advance Beneficiary Notice form is required.**

*Note—Bolded diagnoses below have the highest utilization*

### Code | Description
--- | ---
C22.1 | Intrahepatic bile duct carcinoma
C23 | Malignant neoplasm of gallbladder
C24.0 | Malignant neoplasm of extrahepatic bile duct
C24.1 | Malignant neoplasm of ampulla of Vater
C24.9 | Malignant neoplasm of biliary tract, unspecified
C25.0 | Malignant neoplasm of head of pancreas
C25.1 | Malignant neoplasm of body of pancreas
C25.2 | Malignant neoplasm of tail of pancreas
C25.3 | Malignant neoplasm of pancreatic duct
C25.7 | Malignant neoplasm of other parts of pancreas
C25.8 | Malignant neoplasm of overlapping sites of pancreas
C25.9 | Malignant neoplasm of pancreas, unspecified
C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct
D37.6 | Neoplasm of uncertain behavior of liver, gallbladder and bile ducts
D37.8 | Neoplasm of uncertain behavior of other specified digestive organs
D37.9 | Neoplasm of uncertain behavior of digestive organ, unspecified
G89.3 | Neoplasm related pain (acute) (chronic)
R97.8 | Other abnormal tumor markers
Z85.07 | Personal history of malignant neoplasm of pancreas
Z85.09 | Personal history of malignant neoplasm of other digestive organs

Please refer to the Limitations or Utilization Guidelines section on previous page(s) for frequency information.

Visit [QuestDiagnostics.com/MLCP](http://www.QuestDiagnostics.com/MLCP) to view current limited coverage tests, reference guides, and policy information.

To view the complete policy and the full list of medically supportive codes, please refer to the CMS website reference [www.cms.gov](http://www.cms.gov).

**Disclaimer:**
This diagnosis code reference guide is provided as an aid to physicians and office staff in determining when an ABN (Advance Beneficiary Notice) is necessary. Diagnosis codes must be applicable to the patient’s symptoms or conditions and must be consistent with documentation in the patient’s medical record. Quest Diagnostics does not recommend any diagnosis codes and will only submit diagnosis information provided to us by the ordering physician or his/her designated staff. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

© 2016 Quest Diagnostics Incorporated. All rights reserved.